• English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
On January 22, Fosun Pharma (02196.HK) announced its plan to spin off its subsidiary, Fosun Antgene, for a listing on the Main Board of the Hong Kong Stock Exchange. Following the spin-off, Fosun Pharmas shareholding structure will not undergo significant changes, and it is expected to maintain control over Fosun Antgene.On January 22, Xiaomi Corporation (01810.HK) announced that it has entered into an agreement with an independent brokerage firm to repurchase up to HK$2.5 billion worth of Class B ordinary shares on the Hong Kong Stock Exchange. The automatic share repurchase scheme will commence on January 23, 2026, and will end at the earliest of the following dates: the day before the 2026 Annual General Meeting of Shareholders, when the repurchase amount reaches HK$2.5 billion, or early termination in accordance with the terms of the brokerage agreement. Xiaomi Corporation has applied for and received an exemption allowing the share repurchase during the restricted period. The company believes this scheme demonstrates confidence in its business prospects and is in the best interests of shareholders as a whole.S&P: Strong Nordic banks are poised for growth in 2026.On January 22, Fosun Pharma announced that its subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration (NMPA) for its drug registration application for norepinephrine bitartrate injection. The approved indications include blood pressure recovery in acute hypotension, adjunctive treatment for cardiac arrest, and blood pressure maintenance after cardiac arrest resuscitation. This drug is a chemical drug independently developed by Fosun Pharma, with cumulative R&D investment of approximately RMB 8.74 million as of December 2025. According to IQVIA CHPA data, the drugs sales in China in 2024 were approximately RMB 1.811 billion.According to Hong Kong Stock Exchange filings, Xiaomi Group repurchased 5.7 million Class B shares on January 22, spending HK$200.7 million.

Gold Price Prediction: The XAU/USD pair will go below $1700 after a positive NFP report, followed by the CPI

Daniel Rogers

Oct 10, 2022 11:23

 154.png

 

The gold price declined after the U.S. Labor Department released employment data that exceeded expectations, thereby validating the Fed's need for additional tightening and supporting the dollar. Consequently, XAU/USD is currently trading at approximately $1690, below its initial price.

 

Prior to the announcement of the US Nonfarm Payrolls report, the price of gold hovered around $1710. Gold's initial reaction to the headline, however, was a decline into the $1700 region, but this initial movement quickly vanished. In a volatile reaction, it extended its losses below $1700 at the time of typing.

 

US Bureau of Labor Statistics (BLS) data revealed that the US economy added 263K new jobs, above predictions of 250K, while the unemployment rate decreased to 3.5% from 3.7%. Even while the reading is lower than August's, it was above expectations, which would strengthen the case for a Federal Reserve rate hike.

 

In the meanwhile, money market futures have put in a 92% likelihood of a Fed rate hike of 75 basis points, up from 85.5% prior to the US Nonfarm Payrolls report.

 

US Treasury bond yields rose, with the 10-year US Treasury bond yield increasing three basis points to 3.865%, while the US Dollar Index, a measure of the dollar's value vs six other currencies, rose 0.28% to 112.565.

 

Now that the US Nonfarm Payrolls report is in the rearview mirror, the next significant events on the US calendar are the September CPI statistics and the University of Michigan Consumer Sentiment study, both of which will take place in the coming week.